this post was submitted on 07 Jul 2023
427 points (98.9% liked)

World News

38554 readers
3545 users here now

A community for discussing events around the World

Rules:

We ask that the users report any comment or post that violate the rules, to use critical thinking when reading, posting or commenting. Users that post off-topic spam, advocate violence, have multiple comments or posts removed, weaponize reports or violate the code of conduct will be banned.

All posts and comments will be reviewed on a case-by-case basis. This means that some content that violates the rules may be allowed, while other content that does not violate the rules may be removed. The moderators retain the right to remove any content and ban users.


Lemmy World Partners

News [email protected]

Politics [email protected]

World Politics [email protected]


Recommendations

For Firefox users, there is media bias / propaganda / fact check plugin.

https://addons.mozilla.org/en-US/firefox/addon/media-bias-fact-check/

founded 1 year ago
MODERATORS
 

Japanese drugmaker Eisai and US-based Biogen have been working together on advancing research in the space of Alzheimer’s for nearly a decade. Finally, the FDA, granted the fruits of that labor, Leqembi, its blessing for intravenous use. This marks the first approved treatment that can slow the progression of Alzheimer’s.

you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 6 points 1 year ago

Unfortunately this drug and others like it are not a revolution in Alzheimer's treatment. It is VERY questionable if the modest positive impact is worth the known adverse effects, and many in the healthcare industry (myself included) are concerned that these approvals prey on desperate families willing to pay exorbitant prices for any shred of hope.

"Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer’s disease."

https://www.nejm.org/doi/full/10.1056/NEJMoa2212948